These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28323647)

  • 1. Clinical Complications with the Delivery of Inhaled Epoprostenol in the Operating Room.
    Bhatt AM; Stein EJ
    Anesthesiology; 2017 Aug; 127(2):383. PubMed ID: 28323647
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
    Bildirici I; Shumway JB
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit.
    Gillis HC; Fischer G; Gupta S
    Am J Health Syst Pharm; 2018 Feb; 75(4):171-172. PubMed ID: 29436464
    [No Abstract]   [Full Text] [Related]  

  • 4. Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failure.
    Schroeder RA; Wood GL; Plotkin JS; Kuo PC
    Anesth Analg; 2000 Aug; 91(2):291-5. PubMed ID: 10910834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
    Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
    Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous Intraoperative Delivery of Inhaled Epoprostenol and Nitric Oxide in a Neonate for Atrial Septal Defect Closure: First Report of a Novel Technique.
    Windsor J; Ricci M; Aldoss O; Nakamura Y; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2019 Oct; 33(10):2755-2759. PubMed ID: 30472016
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit.
    Haché M; Denault AY; Bélisle S; Couture P; Babin D; Tétrault F; Guimond JG
    Can J Anaesth; 2001 Oct; 48(9):924-9. PubMed ID: 11606352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
    St-Pierre P; Deschamps A; Cartier R; Basmadjian AJ; Denault AY
    J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):723-9. PubMed ID: 23623891
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with ARDS.
    Dahlem P
    Intensive Care Med; 1999 Dec; 25(12):1474-5. PubMed ID: 10660861
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.
    Parameswaran K; Purcell I; Farrer M; Holland C; Taylor IK; Keaney NP
    Respir Med; 1999 Feb; 93(2):75-8. PubMed ID: 10464856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
    Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostacyclin in the intensive care setting.
    Ivy DD
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S41-5. PubMed ID: 20216163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rebound effect after prostacyclin inhalation in pulmonary hypertension].
    Moro JA; Almenar L; Morales P; Osa A
    Med Clin (Barc); 2007 Jul; 129(7):279. PubMed ID: 17683713
    [No Abstract]   [Full Text] [Related]  

  • 17. The successful management of severe protamine-induced pulmonary hypertension using inhaled prostacyclin.
    Jerath A; Srinivas C; Vegas A; Brister S
    Anesth Analg; 2010 Feb; 110(2):365-9. PubMed ID: 19933533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhaled epoprostenol.
    Lusardi P; Brown V
    Am J Nurs; 2003 Jul; 103(7):64AA, 64CC, 64EE, 64GG-64HH. PubMed ID: 12865644
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.